The acute myeloid leukemia (AML) market in the eight major markets (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and China) was $2.3 billion in 2022. The AML market will register a CAGR of more than 4% from 2022 to 2032 in the eight major markets (8MM) including the United States, France, Germany, Italy, Spain, the UK, Japan, and Urban China. The AML market research report offers an overview of AML, including epidemiology, symptoms, diagnosis, and disease management. The report offers key topics covered including strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the AML therapeutics market.
read more..